Starpharma, Merck collaborate on new ADCs

By The Science Advisory Board staff writers

February 12, 2021 -- Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's proprietary DEP dendrimer drug delivery technology.

DEP ADCs exploit the potential of Starpharma's DEP technology to provide enhanced characteristics including greater homogeneity, site specific attachment, and higher antibody ratio, compared to conventional ADC approaches, according to the firm.

In previous preclinical studies, DEP ADCs have shown significant tumor regression and outperformed other approved drugs in human ovarian cancer models. Financial details of the agreement were not disclosed.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here